{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-020457","form_type":"8-K","ticker":"SRXH","cik":"0001471727","company_name":"SRx Health Solutions, Inc.","filed_at":"2025-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.471934+00:00","generated_at":"2026-05-17T01:05:56.434278+00:00","sec_items":["1.01","2.03","3.02","5.02","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"SRx Health raises $15.23M in first closing of Series A preferred offering; secures up to $1B equity commitment","bullets":["First closing of private placement: 19,035 Series A Preferred shares and 54.5M warrants for $15.23M; additional closings at investor option up to $30.46M total.","Amendment to July 2025 Purchase Agreement increased total commitment from $50M to $1B; issued $20M convertible promissory note in connection.","Series A Preferred conversion price fixed at $0.6109; warrants exercisable at $0.6109; company seeks stockholder approval to raise authorized common from 200M to 5B shares.","Directors Lionel F. Conacher and David Allen White resigned Oct 31, 2025; committees reconstituted with Michael Young, Simon Conway and Joshua A. Epstein."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-020457","json":"https://secwatch.observer/filing/0001493152-25-020457.json","markdown":"https://secwatch.observer/filing/0001493152-25-020457.md","text":"https://secwatch.observer/filing/0001493152-25-020457.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1471727/000149315225020457/0001493152-25-020457-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1471727/000149315225020457/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:05:56.434278+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6dc012e3d188cc2c23d6a12a63dcf09118492c69","claim":"SRx Health Solutions, Inc. amended credit facility of from $50 million to $1 billion with Investor.","evidence_excerpt":"greement (the “Securities Purchase Agreement”) with certain accredited investors named therein. Pursuant to the Securities Purchase Agreement, up to 38,070 shares of the Company’s Series A convertible preferred stock, par value","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1471727/000149315225020457/0001493152-25-020457-index.htm","confidence":0.7,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"from $50 million to $1 billion"},{"label":"Counterparty","value":"Investor"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"765ced0c98b90c8cc911f42b6dcc302391142ad1","claim":"SRx Health Solutions, Inc. incurred convertible notes of $20 million with Investor.","evidence_excerpt":"the Company issued to Investor a convertible promissory note in the aggregate principal amount of $20 million.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1471727/000149315225020457/0001493152-25-020457-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$20 million"},{"label":"Counterparty","value":"Investor"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"d7590f96c5275238b5fecb2f942ff6de5fe01424","claim":"SRx Health Solutions, Inc. issued 19,035 shares of the Series A Preferred Stock of preferred stock to certain accredited investors for aggregate proceeds of approximately $15.23 million.","evidence_excerpt":"On October 31, 2025, pursuant to the Securities Purchase Agreement, the Company issued and sold, and certain investors purchased, in a private placement (the “Private Placement”): 19,035 shares of the Series A Preferred Stock and 54,527,811 Warrants to purchase shares of Common Stock for aggregate proceeds of approximately $15.23 million","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1471727/000149315225020457/0001493152-25-020457-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"preferred stock"},{"label":"Shares","value":"19,035 shares of the Series A Preferred Stock"},{"label":"Purchaser","value":"certain accredited investors"},{"label":"Consideration","value":"aggregate proceeds of approximately $15.23 million"}],"fact_type":"equity_issuance"},{"claim_id":"ecd6cdf46a766e82825c62f0be6653727deb2853","claim":"SRx Health Solutions, Inc. issued 54,527,811 Warrants to purchase shares of Common Stock of warrant to certain accredited investors for aggregate proceeds of approximately $15.23 million.","evidence_excerpt":"On October 31, 2025, pursuant to the Securities Purchase Agreement, the Company issued and sold, and certain investors purchased, in a private placement (the “Private Placement”): 19,035 shares of the Series A Preferred Stock and 54,527,811 Warrants to purchase shares of Common Stock for aggregate proceeds of approximately $15.23 million","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1471727/000149315225020457/0001493152-25-020457-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"54,527,811 Warrants to purchase shares of Common Stock"},{"label":"Purchaser","value":"certain accredited investors"},{"label":"Consideration","value":"aggregate proceeds of approximately $15.23 million"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}